toreforant (JNJ-38518168) / J&J - LARVOL DELTA

A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma (clinicaltrials.gov) - P2 | N=166 | Completed | Sponsor: Janssen Research & Development, LLC | Phase classification: P2a ➔ P2

Phase classification • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A study to investigate how JNJ-38518168 may affect the plasma levels of methotrexate in rheumatoid arthritis participants (clinicaltrials.gov) - P1, N=16; Recruiting; New P1 trial

New trial • Rheumatoid Arthritis

Toreforant, an orally active histamine H-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study. (PubMed, Inflamm Res) - "While clear biomarker signals associated with toreforant pharmacology in RA patients were not identified, modest associations between biomarkers and clinical response were noted. Synovial expression of interleukins-17A/17F was minimal. Limited sample size warrants cautious interpretation."

Biomarker • Clinical • Journal • P2 data